Amgen

Amgen Inc’s Second Quarter Profit Surpasses Analysts’ Estimates; Company Raises Full Year Forecast

Amgen Inc’s Second Quarter Profit Surpasses Analysts’ Estimates; Company Raises

Thousand Oaks, California based Amgen Inc reported second-quarter profit of $1.87 billion and raised its outlook for the complete year. It expects revenue for the full year to be in a range of $22.5 billion to $22.8 billion, compared to the earlier predictions of revenue in a range of $22.2 to $22.6 billion, in April.

Biologic Drug-Maker Amgen Plans to Trim 12 to 15 Percent Jobs

Biologic Drug-Maker Amgen Plans to Trim 12 to 15 Percent JobsAmgen Inc. the biologic drug-maker says that it plans to trim down its workforce all over the world by 12 to 15% along with closing of four of its sites. This decision came in spite of reporting a strong second-quarter result which beat the expectations of the Wall Street.

Xgeva Manufacturers Build Pressure for FDA’s Approval

Xgeva Manufacturers Build Pressure for FDA’s Approval   As per recent reports, it has been revealed that the US health regulator, Food and Drug Administration, has been asked to reconsider their decision in regard to Amgen Inc’ Drug Xgeva, which is meant for prostate cancer patients.

Syndicate content